102 related articles for article (PubMed ID: 14963350)
1. CA19-9 as a serum marker for poor prognosis in urothelial carcinoma.
Sashide K; Isobe H; Wakumoto Y; Hanazawa K; Fujita K; Fujime M
Urol Int; 2004; 72(2):112-7. PubMed ID: 14963350
[TBL] [Abstract][Full Text] [Related]
2. Clinical usefulness of CEA, CA19-9, and CYFRA 21-1 as tumor markers for urothelial bladder carcinoma.
Washino S; Hirai M; Matsuzaki A; Kobayashi Y
Urol Int; 2011; 87(4):420-8. PubMed ID: 22041857
[TBL] [Abstract][Full Text] [Related]
3. CA19-9 as a serum marker for poor prognosis in urothelial carcinoma.
Suzuki K
Urol Int; 2004; 73(4):357. PubMed ID: 15604583
[No Abstract] [Full Text] [Related]
4. CA19-9 as the most significant prognostic indicator of metastatic colorectal cancer.
Wang WS; Lin JK; Chiou TJ; Liu JH; Fan FS; Yen CC; Lin TC; Jiang JK; Yang SH; Wang HS; Chen PM
Hepatogastroenterology; 2002; 49(43):160-4. PubMed ID: 11941943
[TBL] [Abstract][Full Text] [Related]
5. High Serum CA19-9 Concentration Indicates High Chemosensitivity and Better Survival in Advanced Urothelial Carcinoma.
Yaegashi H; Izumi K; Kadomoto S; Naito R; Makino T; Iwamoto H; Nohara T; Shigehara K; Kadono Y; Mizokami A
Anticancer Res; 2019 Jan; 39(1):375-380. PubMed ID: 30591483
[TBL] [Abstract][Full Text] [Related]
6. Significance of serum concentrations of E-selectin and CA19-9 in the prognosis of colorectal cancer.
Sato H; Usuda N; Kuroda M; Hashimoto S; Maruta M; Maeda K
Jpn J Clin Oncol; 2010 Nov; 40(11):1073-80. PubMed ID: 20576794
[TBL] [Abstract][Full Text] [Related]
7. Lymphovascular invasion is independently associated with poor prognosis in patients with localized upper urinary tract urothelial carcinoma treated surgically.
Saito K; Kawakami S; Fujii Y; Sakura M; Masuda H; Kihara K
J Urol; 2007 Dec; 178(6):2291-6; discussion 2296. PubMed ID: 17936818
[TBL] [Abstract][Full Text] [Related]
8. Preoperative serum level of CA19-9 predicts recurrence after curative surgery in node-negative colorectal cancer patients.
Nakagoe T; Sawai T; Tsuji T; Jibiki MA; Nanashima A; Yamaguchi H; Yasutake T; Ayabe H; Arisawa K
Hepatogastroenterology; 2003; 50(51):696-9. PubMed ID: 12828063
[TBL] [Abstract][Full Text] [Related]
9. The role of lymphovascular invasion in predicting the prognosis of clinically localized upper tract urothelial carcinoma (pT1-3cN0M0).
Lin WC; Hu FC; Chung SD; Chueh SC; Pu YS; Huang KH
J Urol; 2008 Sep; 180(3):879-84; discussion 884-5. PubMed ID: 18635224
[TBL] [Abstract][Full Text] [Related]
10. Clinical evaluation of serum and immunohistochemical expression of SCC and CA19-9 in radiation therapy for cervical cancer.
Abe A; Nakano T; Morita S; Oka K
Anticancer Res; 1999; 19(1B):829-36. PubMed ID: 10216501
[TBL] [Abstract][Full Text] [Related]
11. Multivariate analysis of the prognostic value of CEA and CA 19-9 serum levels in colorectal cancer.
Reiter W; Stieber P; Reuter C; Nagel D; Lau-Werner U; Lamerz R
Anticancer Res; 2000; 20(6D):5195-8. PubMed ID: 11326694
[TBL] [Abstract][Full Text] [Related]
12. Loss of uroplakin III expression is associated with a poor prognosis in patients with urothelial carcinoma of the upper urinary tract.
Ohtsuka Y; Kawakami S; Fujii Y; Koga F; Saito K; Ando N; Takizawa T; Kageyama Y; Kihara K
BJU Int; 2006 Jun; 97(6):1322-6. PubMed ID: 16686732
[TBL] [Abstract][Full Text] [Related]
13. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer.
Ni XG; Bai XF; Mao YL; Shao YF; Wu JX; Shan Y; Wang CF; Wang J; Tian YT; Liu Q; Xu DK; Zhao P
Eur J Surg Oncol; 2005 Mar; 31(2):164-9. PubMed ID: 15698733
[TBL] [Abstract][Full Text] [Related]
14. Expression of carbohydrate antigens (SSEA-1, sialyl-Lewis X, DU-PAN-2 and CA19-9) and E-selectin in urothelial carcinoma of the renal pelvis, ureter, and urinary bladder.
Kajiwara H; Yasuda M; Kumaki N; Shibayama T; Osamura Y
Tokai J Exp Clin Med; 2005 Sep; 30(3):177-82. PubMed ID: 16285609
[TBL] [Abstract][Full Text] [Related]
15. The impact of preoperative serum C-reactive protein on the prognosis of patients with upper urinary tract urothelial carcinoma treated surgically.
Saito K; Kawakami S; Ohtsuka Y; Fujii Y; Masuda H; Kumagai J; Kobayashi T; Kageyama Y; Kihara K
BJU Int; 2007 Aug; 100(2):269-73. PubMed ID: 17488302
[TBL] [Abstract][Full Text] [Related]
16. The use of tumor markers as predictors of prognosis in gastric cancer.
Mihmanli M; Dilege E; Demir U; Coskun H; Eroglu T; Uysalol MD
Hepatogastroenterology; 2004; 51(59):1544-7. PubMed ID: 15362797
[TBL] [Abstract][Full Text] [Related]
17. The impact of resection margin status and postoperative CA19-9 levels on survival and patterns of recurrence after postoperative high-dose radiotherapy with 5-FU-based concurrent chemotherapy for resectable pancreatic cancer.
Kinsella TJ; Seo Y; Willis J; Stellato TA; Siegel CT; Harpp D; Willson JK; Gibbons J; Sanabria JR; Hardacre JM; Schulak JP
Am J Clin Oncol; 2008 Oct; 31(5):446-53. PubMed ID: 18838880
[TBL] [Abstract][Full Text] [Related]
18. Clinical use of serum CA-125 levels in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder.
Kouba EJ; Lentz A; Wallen EM; Pruthi RS
Urol Oncol; 2009; 27(5):486-90. PubMed ID: 18555706
[TBL] [Abstract][Full Text] [Related]
19. Value of serum carbohydrate antigen 19-9 for predicting extrahepatic metastasis in patients with liver metastasis from colorectal carcinoma.
Sasaki A; Kawano K; Inomata M; Shibata K; Matsumoto T; Kitano S
Hepatogastroenterology; 2005; 52(66):1814-9. PubMed ID: 16334783
[TBL] [Abstract][Full Text] [Related]
20. Multivariate analysis of occult lymph node metastasis as a prognostic indicator for patients with squamous cell carcinoma of the oral cavity.
Hiratsuka H; Miyakawa A; Nakamori K; Kido Y; Sunakawa H; Kohama G
Cancer; 1997 Aug; 80(3):351-6. PubMed ID: 9241067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
